Form 4: Dyne Therapeutics Director Granted Stock Options

Dyne Therapeutics director Vikram Karnani was granted 59,665 stock options with an exercise price of $20.78, vesting over three years.

Summary

• Vikram Karnani, a Director of Dyne Therapeutics, Inc. (DYN), was granted 59,665 stock options.
• The stock options have an exercise price of $20.78 per share.
• The grant date for these options was December 22, 2025.
• The shares underlying the option are scheduled to vest over three years in equal monthly installments, concluding on December 22, 2028.
• The options have an expiration date of December 21, 2035.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged purchase or sale plan.

Sentiment

Score: 6

Explanation: The filing reports a routine insider equity grant, which is a standard compensation practice. It is neutral to slightly positive as it aligns director interests with shareholders, but does not contain new operational or financial performance information.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The transaction was executed under a Rule 10b5-1(c) plan, which can indicate a pre-planned and transparent approach to insider equity transactions.

Future Outlook

The vesting schedule for the granted stock options indicates that the director's full beneficial ownership of the underlying shares will materialize over the next three years, concluding in December 2028, subject to continued service.

Industry Context

The grant of stock options to a director is a standard practice in the biotechnology and pharmaceutical industries, serving as a common form of equity compensation to attract, retain, and incentivize key leadership by aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• Granting stock options to directors is a common form of compensation across publicly traded companies, particularly in growth-oriented sectors like biotechnology, to align executive and director incentives with shareholder returns.
• The vesting schedule over three years is a typical structure for such equity grants, promoting long-term commitment and performance.

Related Party Transactions

• The grant of stock options to Vikram Karnani, a Director, constitutes a related party transaction, which is a standard form of director compensation.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's long-term interests with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest in equal monthly installments through December 22, 2028, contingent on Vikram Karnani's continued service as a director.

Key Dates

Keywords

Dyne Therapeutics, DYN, stock option, insider transaction, Vikram Karnani, director compensation, equity grant, Form 4, beneficial ownership